| 1.265 -0.015 (-1.17%) | 11-25 13:31 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.78 |
1-year : | 2.1 |
| Resists | First : | 1.53 |
Second : | 1.8 |
| Pivot price | 1.27 |
|||
| Supports | First : | 1.09 | Second : | 0.9 |
| MAs | MA(5) : | 1.19  |
MA(20) : | 1.36 |
| MA(100) : | 1.29 |
MA(250) : | 1.16 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 26.5 |
D(3) : | 16.8 |
| RSI | RSI(14): 42.8 |
|||
| 52-week | High : | 2.43 | Low : | 0.7 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CHRS ] has closed above bottom band by 46.2%. Bollinger Bands are 39.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.3 - 1.3 | 1.3 - 1.31 |
| Low: | 1.14 - 1.14 | 1.14 - 1.15 |
| Close: | 1.27 - 1.28 | 1.28 - 1.29 |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Fri, 14 Nov 2025
Revenues Working Against Coherus Oncology, Inc.'s (NASDAQ:CHRS) Share Price Following 26% Dive - simplywall.st
Sat, 08 Nov 2025
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates - MSN
Thu, 06 Nov 2025
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewswire
Thu, 06 Nov 2025
Coherus Oncology: Q3 Earnings Snapshot - Connecticut Post
Thu, 06 Nov 2025
Coherus Oncology (NASDAQ: CHRS) names Arvind Sood for Corp. Dev., IR & Government Affairs - Stock Titan
Thu, 06 Nov 2025
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 121 (M) |
| Shares Float | 113 (M) |
| Held by Insiders | 12.4 (%) |
| Held by Institutions | 43.4 (%) |
| Shares Short | 30,100 (K) |
| Shares Short P.Month | 31,140 (K) |
| EPS | 0.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.75 |
| Profit Margin | 55.7 % |
| Operating Margin | -365 % |
| Return on Assets (ttm) | -10.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 91.1 % |
| Gross Profit (p.s.) | 1.29 |
| Sales Per Share | 2.29 |
| EBITDA (p.s.) | -0.67 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -90 (M) |
| Levered Free Cash Flow | 30 (M) |
| PE Ratio | 2.28 |
| PEG Ratio | 0 |
| Price to Book value | 1.67 |
| Price to Sales | 0.54 |
| Price to Cash Flow | -1.69 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|